Why the study?
The study aimed to identify factors associated with the use of novel diabetes medications among patients hospitalized under general internal medicine.
What factors predict the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in hospitalized adults with type 2 diabetes?
What factors predict the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in hospitalized adults with type 2 diabetes?
Answers are grounded in this paper and cite their sources.
Novel diabetes medications with cardiovascular benefits (SGLT2 inhibitors and GLP1 receptor agonists) are significantly underutilized in hospitalized patients with T2DM.
AIMS: To identify factors associated with use of novel diabetes medications among patients hospitalized under general internal medicine. METHODS: We conducted a cohort study of patients with type 2 diabetes mellitus (T2DM) hospitalized in Ontario, Canada between 2015 and 2020. We evaluated the patient- and physician-level factors associated with sodium-glucose cotransporter 2 inhibitor (SGLT2) and glucagon-like peptide 1 receptor agonist (GLP1R) use using a multivariable logistic regression model. RESULTS: There were 253,152 hospitalizations and 68,126 involved patients who had T2DM. Prior to discharge, 3.7 % (N = 2490) of patients with T2DM received an SGLT2 and 0.2 % (N = 121) received a GLP1R. The strongest predictors for receiving a novel diabetes medication were hemoglobin A1C > 9.0 % (Odds Ratio (OR) = 1.81, 95 % Confidence Interval (CI) 1.28, 2.60) and patients aged 40-60 compared with patients <40 years old (OR = 1.81, 95 % CI 1.33, 2.68). The strongest predictors for not receiving a novel diabetes medication were dementia (OR = 0.47, 95 % CI 0.39, 0.56) and creatinine ≥200 μmol/L (OR = 0.11, 95 % CI 0.08, 0.15). Overall, 46.8 % of patients hospitalized with T2DM not receiving a novel diabetes medication would potentially benefit from an SGLT2 inhibitor. CONCLUSIONS: Novel diabetes medications were rarely continued or initiated during hospitalization despite a high prevalence of cardiovascular disease, raising the concern for systematic under-utilization after discharge.
No takes yet. Share an insight, caveat, or question.
Raudanskis et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: